The common name “major triple-positive” refers to the three indicators of positive hepatitis B surface antigen (HBsAg), hepatitis B e antigen (HBeAg) and hepatitis B core antibody (anti-HBc). Small triple positive” refers to positive HBsAg, hepatitis B e antibody (anti-HBe) and anti-HBc indicators. Previously, “major triple-positive” means that the hepatitis B virus is infected, actively replicating and infectious. A “minor triple-positive” indicates that the hepatitis condition has improved, the hepatitis B virus has stopped replicating, and is not contagious. Recently, a large number of studies have shown that the change from “major triple positive” to “minor triple positive” in patients with chronic hepatitis B does not mean that hepatitis B virus replication has completely stopped, but in most cases it only means that hepatitis B virus replication has decreased. A small number of patients with “minor triple-positive” have persistent positive serum HBV DNA, active viral replication, more severe disease, and rapid disease progression, as seen in viral mutation. In acute hepatitis B and HBsAg carriers, a shift from “major triplet” to “minor triplet” is a sign of good prognosis. At the end of antiviral therapy for chronic hepatitis B, the patient’s serum changes from “major triplet” to “minor triplet”, indicating that the treatment has achieved some effect. Anyone who carries the hepatitis B virus may pass it on to others, so they are all sources of infection, and the more viruses they carry, the more infectious they are. The hepatitis B virus is mainly found in the liver and blood, and can reach all body fluids, such as saliva, sweat, semen, vaginal secretions, etc., with the blood. So theoretically all these body fluids are infectious. The hepatitis B virus must enter the bloodstream in order to cause infection, but the hepatitis B virus itself is not motile and cannot penetrate the normal skin and mucous membrane of the human body to enter the bloodstream by itself, but must pass through the broken skin, mucous membrane and blood vessels to enter the bloodstream. After infection with hepatitis B virus, there are two types of regression: one is rapid healing and the production of protective antibodies, namely anti-HBs and non-protective antibodies, namely -HBc, or possibly only anti-HBc; the other regression is to become chronic and carry the hepatitis B virus for a long time (mostly for life). Most adults (85-90%) who are infected with hepatitis B virus recover quickly and spontaneously without becoming chronic. Infants and children who are infected with the hepatitis B virus, on the other hand, can easily become chronic and carry the virus for a long time. Infections between couples are adult infections, so not many of them turn into chronic hepatitis B after infection, generally less than 20%. In summary, hepatitis B is not very likely to be transmitted in daily life, and it is not easy to be infected by general contact, sharing meals, laundry and cooking. The likelihood of infection between husband and wife is slightly higher, but the majority of adults who are infected can be cured naturally. The best way to prevent hepatitis B is not to passively isolate patients, but to protect normal people who have not yet been infected with hepatitis B. That is, normal people should be given the hepatitis B vaccine to produce anti-hepatitis B antibodies and lymphocytes, so that even if they have close contact with hepatitis B patients, or even if the hepatitis B virus enters their bodies, they will generally not be infected with hepatitis B again, because the anti-hepatitis B antibodies and lymphocytes can quickly and completely kill the hepatitis B virus that enters their bodies. The anti-hepatitis B antibodies and lymphocytes can quickly and completely kill the hepatitis B virus that enters the body. This is why it is now recommended that all normal people who do not have hepatitis B be vaccinated against it, which is much better than passively avoiding it. If one person in the family or unit has hepatitis B, the others should get the vaccine and then we can still share meals, work together and live together. The test results of “major” or “minor” hepatitis B only indicate the amount of virus in the body, not the presence of liver damage, which is the main indication for our treatment. Therefore, regardless of whether the patient is a “major or minor triple-positive”, if there is no evidence of liver damage, antiviral treatment is not supported at this time; conversely, treatment is necessary regardless of whether the patient is a “major or minor triple-positive”.